B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

SLC5A2

MOLECULAR TARGET

solute carrier family 5 member 2

UniProt: P31639NCBI Gene: 652415 compounds

SLC5A2 (solute carrier family 5 member 2) is targeted by 15 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting SLC5A2

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1dapagliflozin3.8345
2phlorizin3.7843
3phloretin3.7140
4kurarinone2.4811
5sergliflozin a2.4010
6sophoraflavanone g2.309
7canagliflozin anhydrous2.208
8ertugliflozin1.956
9sergliflozin etabonate1.956
10ipragliflozin1.956
11luseogliflozin1.795
12sotagliflozin1.795
13empagliflozin0.691
14Canagliflozin0.691
15phlorhizin0.691

About SLC5A2 as a Drug Target

SLC5A2 (solute carrier family 5 member 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 15 compounds with documented SLC5A2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

SLC5A2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.